Arbutus to Report Third Quarter 2022 Financial Results and Provide Corporate UpdateGlobeNewsWire • 10/26/22
Gaston Picchio, PhD, Chief Development Officer, to Depart Arbutus at Year EndGlobeNewsWire • 09/30/22
Arbutus Biopharma Announces Issuance of a New Key U.S. Patent Related to AB-729GlobeNewsWire • 08/30/22
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/04/22
Arbutus Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/04/22
Arbutus to Report Second Quarter 2022 Financial Results and Provide Corporate UpdateGlobeNewsWire • 07/21/22
Arbutus Biopharma Provides Update on the Phase 2A Combination Trial with AB-729 and a Capsid InhibitorGlobeNewsWire • 07/20/22
This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis BBenzinga • 06/28/22
Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical UpdateGlobeNewsWire • 06/25/22
Arbutus to Present Seven Scientific Posters at EASL International Liver Congress™ 2022GlobeNewsWire • 06/08/22
Arbutus Announces Abstract Selected for Publication at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • 05/26/22
Arbutus Biopharma Corp (ABUS) CEO William Collier on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/05/22
Arbutus Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/05/22
Arbutus to Report First Quarter 2022 Financial Results and Provide Corporate UpdateGlobeNewsWire • 04/21/22
Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of InterestSeeking Alpha • 03/07/22
Arbutus Biopharma Corporation (ABUS) CEO William Collier on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/03/22
Arbutus Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/03/22